AtriCure, Inc. (ATRC)
USD 30.25
(-3.97%)
USD 30.25
(-3.97%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 613.93 Million USD | 4.87% |
| 2022 | 585.44 Million USD | -4.85% |
| 2021 | 615.31 Million USD | -13.89% |
| 2020 | 714.53 Million USD | 28.08% |
| 2019 | 557.88 Million USD | 56.37% |
| 2018 | 356.75 Million USD | 33.27% |
| 2017 | 267.7 Million USD | -3.15% |
| 2016 | 276.42 Million USD | 1.22% |
| 2015 | 273.09 Million USD | 72.4% |
| 2014 | 158.4 Million USD | 41.5% |
| 2013 | 111.94 Million USD | 245.19% |
| 2012 | 32.43 Million USD | -4.22% |
| 2011 | 33.85 Million USD | 0.42% |
| 2010 | 33.71 Million USD | -3.62% |
| 2009 | 34.98 Million USD | -19.34% |
| 2008 | 43.36 Million USD | -5.87% |
| 2007 | 46.07 Million USD | 17.75% |
| 2006 | 39.12 Million USD | -21.81% |
| 2005 | 50.04 Million USD | 293.07% |
| 2004 | 12.73 Million USD | -13.74% |
| 2003 | 14.75 Million USD | -16.08% |
| 2002 | 17.58 Million USD | 757.44% |
| 2001 | 2.05 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 597.27 Million USD | 0.95% |
| 2024 Q1 | 591.62 Million USD | -3.63% |
| 2024 Q3 | 615.06 Million USD | 2.98% |
| 2023 Q3 | 600.27 Million USD | 1.03% |
| 2023 Q4 | 613.93 Million USD | 2.28% |
| 2023 FY | 613.93 Million USD | 4.87% |
| 2023 Q1 | 583.1 Million USD | -0.4% |
| 2023 Q2 | 594.17 Million USD | 1.9% |
| 2022 Q4 | 585.44 Million USD | 0.61% |
| 2022 Q1 | 584.98 Million USD | -4.93% |
| 2022 Q3 | 581.91 Million USD | -0.93% |
| 2022 FY | 585.44 Million USD | -4.85% |
| 2022 Q2 | 587.38 Million USD | 0.41% |
| 2021 FY | 615.31 Million USD | -13.89% |
| 2021 Q1 | 699.9 Million USD | -2.05% |
| 2021 Q2 | 701.07 Million USD | 0.17% |
| 2021 Q3 | 612.96 Million USD | -12.57% |
| 2021 Q4 | 615.31 Million USD | 0.38% |
| 2020 Q2 | 704.23 Million USD | 33.44% |
| 2020 FY | 714.53 Million USD | 28.08% |
| 2020 Q1 | 527.73 Million USD | -5.4% |
| 2020 Q4 | 714.53 Million USD | 0.95% |
| 2020 Q3 | 707.79 Million USD | 0.51% |
| 2019 Q2 | 343.12 Million USD | 1.41% |
| 2019 FY | 557.88 Million USD | 56.37% |
| 2019 Q1 | 338.36 Million USD | -5.16% |
| 2019 Q4 | 557.88 Million USD | -0.51% |
| 2019 Q3 | 560.75 Million USD | 63.43% |
| 2018 Q3 | 271.96 Million USD | 0.41% |
| 2018 FY | 356.75 Million USD | 33.27% |
| 2018 Q4 | 356.75 Million USD | 31.18% |
| 2018 Q2 | 270.84 Million USD | 0.42% |
| 2018 Q1 | 269.7 Million USD | 0.75% |
| 2017 Q3 | 268.45 Million USD | -0.02% |
| 2017 Q4 | 267.7 Million USD | -0.28% |
| 2017 Q1 | 266.42 Million USD | -3.62% |
| 2017 FY | 267.7 Million USD | -3.15% |
| 2017 Q2 | 268.51 Million USD | 0.78% |
| 2016 Q4 | 276.42 Million USD | -1.04% |
| 2016 Q3 | 279.31 Million USD | -0.78% |
| 2016 Q2 | 281.51 Million USD | 7.57% |
| 2016 Q1 | 261.71 Million USD | -4.17% |
| 2016 FY | 276.42 Million USD | 1.22% |
| 2015 Q4 | 273.09 Million USD | 64.87% |
| 2015 Q1 | 153.4 Million USD | -3.16% |
| 2015 Q2 | 159.3 Million USD | 3.85% |
| 2015 Q3 | 165.64 Million USD | 3.98% |
| 2015 FY | 273.09 Million USD | 72.4% |
| 2014 Q3 | 157.14 Million USD | 0.77% |
| 2014 Q1 | 158.55 Million USD | 41.63% |
| 2014 FY | 158.4 Million USD | 41.5% |
| 2014 Q2 | 155.93 Million USD | -1.65% |
| 2014 Q4 | 158.4 Million USD | 0.8% |
| 2013 Q2 | 57.48 Million USD | -1.11% |
| 2013 Q4 | 111.94 Million USD | 94.23% |
| 2013 FY | 111.94 Million USD | 245.19% |
| 2013 Q1 | 58.12 Million USD | 79.23% |
| 2013 Q3 | 57.63 Million USD | 0.27% |
| 2012 Q4 | 32.43 Million USD | -3.89% |
| 2012 Q2 | 36.02 Million USD | -1.54% |
| 2012 Q1 | 36.58 Million USD | 8.06% |
| 2012 FY | 32.43 Million USD | -4.22% |
| 2012 Q3 | 33.74 Million USD | -6.33% |
| 2011 FY | 33.85 Million USD | 0.42% |
| 2011 Q4 | 33.85 Million USD | -0.77% |
| 2011 Q3 | 34.12 Million USD | -5.58% |
| 2011 Q2 | 36.13 Million USD | -1.62% |
| 2011 Q1 | 36.73 Million USD | 8.94% |
| 2010 Q1 | 32.98 Million USD | -5.7% |
| 2010 FY | 33.71 Million USD | -3.62% |
| 2010 Q4 | 33.71 Million USD | -5.49% |
| 2010 Q3 | 35.67 Million USD | 2.65% |
| 2010 Q2 | 34.75 Million USD | 5.35% |
| 2009 Q3 | 36.07 Million USD | 3.7% |
| 2009 FY | 34.98 Million USD | -19.34% |
| 2009 Q1 | 27.97 Million USD | -35.49% |
| 2009 Q2 | 34.78 Million USD | 24.35% |
| 2009 Q4 | 34.98 Million USD | -3.03% |
| 2008 Q2 | 40.6 Million USD | -6.9% |
| 2008 FY | 43.36 Million USD | -5.87% |
| 2008 Q4 | 43.36 Million USD | -4.98% |
| 2008 Q3 | 45.64 Million USD | 12.4% |
| 2008 Q1 | 43.61 Million USD | -5.32% |
| 2007 Q4 | 46.07 Million USD | 0.28% |
| 2007 Q2 | 49.77 Million USD | 37.39% |
| 2007 Q1 | 36.23 Million USD | -7.4% |
| 2007 FY | 46.07 Million USD | 17.75% |
| 2007 Q3 | 45.94 Million USD | -7.71% |
| 2006 FY | 39.12 Million USD | -21.81% |
| 2006 Q1 | 46.97 Million USD | -6.13% |
| 2006 Q3 | 41.5 Million USD | -5.98% |
| 2006 Q2 | 44.13 Million USD | -6.03% |
| 2006 Q4 | 39.12 Million USD | -5.72% |
| 2005 Q2 | 12.51 Million USD | 0.86% |
| 2005 Q4 | 50.04 Million USD | -7.86% |
| 2005 Q1 | 12.4 Million USD | -2.54% |
| 2005 Q3 | 54.31 Million USD | 333.99% |
| 2005 FY | 50.04 Million USD | 293.07% |
| 2004 FY | 12.73 Million USD | -13.74% |
| 2004 Q4 | 12.73 Million USD | 0.0% |
| 2003 FY | 14.75 Million USD | -16.08% |
| 2002 FY | 17.58 Million USD | 757.44% |
| 2001 FY | 2.05 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 180.36 Million USD | -240.376% |
| AngioDynamics, Inc. | 317.67 Million USD | -93.26% |
| Avinger, Inc. | 13.77 Million USD | -4358.475% |
| Azenta, Inc. | 2.88 Billion USD | 78.725% |
| BioLife Solutions, Inc. | 412.71 Million USD | -48.755% |
| The Cooper Companies, Inc. | 11.65 Billion USD | 94.734% |
| Daxor Corporation | 34.86 Million USD | -1660.674% |
| Ekso Bionics Holdings, Inc. | 28.91 Million USD | -2023.01% |
| Femasys Inc. | 27.75 Million USD | -2111.903% |
| GlucoTrack, Inc. | 4.9 Million USD | -12416.453% |
| Harvard Bioscience, Inc. | 137.36 Million USD | -346.932% |
| Hologic, Inc. | 9.15 Billion USD | 93.295% |
| ICU Medical, Inc. | 4.37 Billion USD | 85.978% |
| Intuitive Surgical, Inc. | 15.44 Billion USD | 96.024% |
| KORU Medical Systems, Inc. | 28.46 Million USD | -2057.101% |
| LeMaitre Vascular, Inc. | 346.77 Million USD | -77.039% |
| Innovative Eyewear, Inc. | 6.21 Million USD | -9772.254% |
| Innovative Eyewear, Inc. | 6.21 Million USD | -9772.254% |
| Masimo Corporation | 3.04 Billion USD | 79.815% |
| Microbot Medical Inc. | 8.32 Million USD | -7272.787% |
| Meihua International Medical Technologies Co., Ltd. | 171.91 Million USD | -257.113% |
| Merit Medical Systems, Inc. | 2.32 Billion USD | 73.597% |
| Nephros, Inc. | 11.86 Million USD | -5076.056% |
| NovoCure Limited | 1.14 Billion USD | 46.434% |
| NEXGEL, Inc. | 9.95 Million USD | -6067.072% |
| NEXGEL, Inc. | 9.95 Million USD | -6067.072% |
| Singular Genomics Systems, Inc. | 265.46 Million USD | -131.265% |
| OraSure Technologies, Inc. | 482.84 Million USD | -27.149% |
| Pro-Dex, Inc. | 54.21 Million USD | -1032.507% |
| Pulse Biosciences, Inc. | 60.8 Million USD | -909.69% |
| Predictive Oncology Inc. | 14.41 Million USD | -4158.316% |
| Precision Optics Corporation, Inc. | 16.91 Million USD | -3530.033% |
| QuidelOrtho Corporation | 8.56 Billion USD | 92.83% |
| Repligen Corporation | 2.82 Billion USD | 78.263% |
| Sanara MedTech Inc. | 73.87 Million USD | -731.085% |
| STAAR Surgical Company | 488.69 Million USD | -25.628% |
| Sharps Technology, Inc. | 11.78 Million USD | -5107.55% |
| Utah Medical Products, Inc. | 135.45 Million USD | -353.227% |
| DENTSPLY SIRONA Inc. | 7.37 Billion USD | 91.67% |
| Jin Medical International Ltd. | 32.9 Million USD | -1765.859% |